Background: Retinoids such as retinoic acid (RA), retinol (ROL) and retinaldehyde (RAL) are currently used in many formulations and indications ranging form acne to skin aging. Most if not all their pharmacological activities occur through binding to nuclear receptors with subsequent modulation of the activities of several genes. Little attention has been given to the many other potential actions on the surface of the skin. Aim: To analyse the potential anti-infective activities of topical ROL, RAL and RA. Methods: Microbial minimal inhibitory concentrations (MIC) of ROL, RAL and RA were determined by a microdilution method on reference strains including Staphylococcus aureus, Staphylococcus epidermidis, Micrococcus flavus, Propionibacterium acnes, Micrococcus luteus, Enterococcus faecium,Staphylococcus hominis, Escherichia coli, Pseudomonas aeruginosa, Candida albicans and 133 clinical strains including methicillin-resistant S. aureus, methicillin-sensitive S. aureus, coagulase-negative Staphylococcus, Streptococcus group B, Enterococcus faecalis, vancomycin-resitant E. faecalis, vancomycin-resistant E. faecium and Pseudomonas/Klebsiella. In two clinical trials in healthy human volunteers, skin bacterial densities were evaluated in samples obtained with the cylinder scrub method: (1) 2 and 5 h after a single application of 0.05% RAL or vehicle on the forearm and (2) in a single-blind randomized study where 0.05% RAL or vehicle were applied daily for 2 weeks on the forehead of 22 volunteers. Paired results from treated (or vehicle) and untreated areas were analysed. Results: Of the three retinoids tested, only RAL showed a significant in vitro antibacterial activity; this activity was found against reference strains of gram-positive bacteria like S. aeureus, Micrococcus spp. or P. acnes. No activity was found against gram-negative bacteria. These results on reference strains were confirmed on 133 clinical isolates. MIC50 and MIC90 values for RAL were 8 and 16 mg/l, respectively, for methicillin-sensitive S. aureus and 4 and 8 mg/l for methicillin-resistant S. aureus. The two in vivo studies showed that areas treated with RAL had a significant decrease in the bacterial counts. In the forehead study, the median decrease was 102 log/cm2 for P. acnes and 101.8 log/cm2 for staphylococci. No resistant bacteria were found after 2 weeks of topical use. Preliminary results suggest that the antibacterial effect of RAL is due, in part, to the aldehyde group in the lateral chain, since non-retinoid pseudo-analogues of the chain, like citral and hexenal, showed a similar antibacterial activity. Conclusion: We have shown that RAL differs from parent natural retinoids such as ROL and RA in demonstrating significant antibacterial activities upon topical use. This activity is likely due to the aldehyde group in the isoprenoic lateral chain, which illustrates the potential bifunctional properties of some retinoids.

Keywords:
Retinaldehyde, Staphylococcus aureus, Micrococcus spp., Propionibacterium acnes
1.
Green HN, Mellanby E: Vitamin A as an anti-infective agent. Br Med J 1928;ii:691–696.
2.
Cohen Be, Elin RJ: Vitamin A induced nonspecific resistance to infection. J Infect Dis 1974;129:597–600.
3.
Krishnan S, Krishnan AD, Mustapha AS, Talwar GP, Ramalingaswami V: Effect of vitamin A and undernutrition on the susceptibility of rodents to a malarial parasite Plasmodium berghei. J Nutr 1976;106:784–791.
4.
Bang FB, Bang BG, Foard M: Acute Newcastle disease virus infection of the upper respiratory tract of the chicken: The effect of diets deficient in vitamin A on the pathogenesis of the infection. Am J Pathol 1975;79:417–424.
5.
Nauss KM, Anderson CA, Connors MW, Newberne PM: Ocular infection with herpes simplex virus (HSV-1) infection. J Nutr 1985;115:1300–1315.
6.
Ross AC, Hämmerling UG: Retinoids and the immune system; in Sporn MB, Roberts AB, Goodman DS (eds): The Retinoids: Biology, Chemistry and Medicine, ed 2. New York, Raven Press, 1994, pp 597–630.
7.
Saurat JH, Didierjean L, Masgrau E, Piletta PA, Jaconi S, Chattellard-Gruaz D, Gumowski D, Massouyé I, Salomon D, Siegenthaler G: Topical retinaldehyde on human skin: Biological effects and tolerance. J Invest Dermatol 1994;103:770–774.
8.
Sorg O, Didierjean L, Saurat JH: Metabolism of topical retinaldehyde. Dermatology 1999;199(suppl 1):13–18.
9.
Didierjean L, Tran C, Sorg O, Saurat JH: Biological activities of topical retinaldehyde. Dermatology 1999;199(suppl 1):19–24.
10.
Pechère M, Pechère JC, Siegenthaler G, Germanier L, Saurat JH: Antibacterial activity of retinaldehyde against Propionibacterium acnes. Dermatology 1999;199(suppl 1):29–31.
11.
National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Approved Standard, ed 2. Villanova, NCCLS, 1990, p 8.
12.
Wiliamson P, Kligman AM: A new method for the quantitative investigation of cutaneous bacteria. J Invest Dermatol 1965;45:498–530.
13.
Flemetakis AC, Tsambaos DG: Effects of synthetic retinoids on the growth of bacteria and their susceptibility to antibodics. J Chemother 1989;1:374–376.
14.
Leyden JJ, James WD: Staphylococcus aureus infection as a complication of isotretinoin therapy. Arch Dermatol 1987;123:606–608.
15.
Saurat J-H: Oral isotretinoin: Where now, where next? Dermatology 1997;195(suppl 1):1–3.
16.
Leyden JJ: Oral isotretinoin: How can we treat difficult acne patients? Dermatology 1997;195(suppl 1):29–33.
17.
Coates P, Adams CA, Cunliffe WJ, McGinley KT, Eady EA, Leyden JJ, Ravenscroft J, Vyakmmam S, Vowels B: Does oral isotretinoin prevent Propionibacterium acnes resistance? Dermatology 1997;195(suppl 1):4–9.
18.
Miller YW, Eady EA, Lacey RW, Cove JH, Joanes DN, Cunliffe WJ: Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother 1996;38:829–837.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.